influenza
acut
respiratori
diseas
major
health
problem
worldwid
sinc
mucos
immun
play
critic
role
protect
influenza
viru
infect
mucos
immun
consid
promis
vaccin
rout
howev
except
liveattenu
vaccin
effect
kill
recombin
mucos
influenza
vaccin
date
outer
membran
vesicl
omv
nanos
vesicl
produc
gramneg
bacteria
contain
variou
bacteri
compon
capabl
stimul
immun
system
host
gener
omv
low
endotox
fmomv
modifi
structur
lipid
moieti
lipopolysaccharid
investig
effect
intranas
vaccin
adjuv
influenza
vaccin
model
model
fmomv
exhibit
reduc
tolllik
receptor
activ
attenu
endotox
compar
nativ
omv
intranas
inject
vaccin
antigen
fmomv
significantli
increas
system
antibodi
cell
respons
mucos
iga
level
frequenc
lungresid
influenzaspecif
cell
addit
number
antigenbear
dendrit
cell
mediastin
lymph
node
significantli
increas
fmomv
coadministr
notabl
mice
coimmun
fmomv
show
significantli
higher
protect
rate
challeng
lethal
dose
homolog
heterolog
influenza
virus
without
advers
effect
result
show
potenti
fmomv
effect
mucos
adjuv
intranas
vaccin
influenza
acut
respiratori
diseas
major
health
problem
worldwid
sinc
mucos
immun
play
critic
role
protect
influenza
viru
infect
mucos
immun
consid
promis
vaccin
rout
howev
except
liveattenu
vaccin
effect
kill
recombin
mucos
influenza
vaccin
date
outer
membran
vesicl
omv
nanos
vesicl
produc
gramneg
bacteria
contain
variou
bacteri
compon
capabl
stimul
immun
system
host
gener
omv
low
endotox
fmomv
modifi
structur
lipid
moieti
lipopolysaccharid
investig
effect
intranas
vaccin
adjuv
influenza
vaccin
model
model
fmomv
exhibit
reduc
tolllik
receptor
activ
attenu
endotox
compar
nativ
omv
intranas
inject
vaccin
antigen
fmomv
significantli
increas
system
antibodi
cell
respons
mucos
iga
level
frequenc
lungresid
influenzaspecif
cell
addit
number
antigenbear
dendrit
cell
mediastin
lymph
node
significantli
increas
fmomv
coadministr
notabl
mice
coimmun
fmomv
show
significantli
higher
protect
rate
challeng
lethal
dose
homolog
heterolog
influenza
virus
without
advers
effect
result
show
potenti
fmomv
effect
mucos
adjuv
intranas
vaccin
elsevi
ltd
right
reserv
influenza
acut
respiratori
diseas
caus
mainli
influenza
b
virus
major
health
problem
worldwid
due
segment
rna
genom
structur
virus
frequent
constantli
alter
antigen
characterist
consequ
chang
infect
pathogen
cope
divers
strain
subtyp
influenza
vaccin
need
induc
crossreact
immun
respons
capabl
cover
wide
rang
subtyp
use
adjuv
alum
improv
potenc
vaccin
term
breadth
magnitud
immun
respons
vaccin
antigen
therefor
efficaci
adjuv
could
breakthrough
develop
univers
influenza
vaccin
mucos
immun
consid
promis
rout
vaccin
deliveri
effici
induc
strong
mucos
immun
result
effici
defens
mucos
infect
compar
system
immun
respons
among
divers
mucos
rout
intranas
deliveri
particularli
advantag
elicit
strongest
respiratori
immun
respons
play
critic
role
protect
respiratori
infect
influenza
two
intranas
influenza
vaccin
flumist
nasovac
current
avail
consist
attenuatedl
virus
addit
licens
vaccin
mani
studi
reveal
possibl
proteinbas
intranas
vaccin
respiratori
pathogen
streptococcu
pneumonia
respiratori
syncyti
viru
howev
approv
intranas
adjuv
capabl
enhanc
immunogen
proteinbas
killedviru
vaccin
antigen
develop
date
outer
membran
vesicl
omv
natur
produc
nanos
vesicl
gramneg
bacteria
contain
variou
bacteri
compon
lipopolysaccharid
lp
lipoprotein
flagellin
monom
bacteri
dna
fragment
due
natur
compon
omv
stimul
host
immun
system
innat
immun
receptor
includ
tolllik
receptor
tlr
nodlik
receptor
nlr
recent
studi
intramuscular
inject
omv
irrelev
antigen
enhanc
antigenspecif
humor
cellular
immun
respons
increas
protect
rate
tumor
viru
challeng
howev
order
use
omv
vaccin
adjuv
deliveri
vehicl
safeti
system
must
address
lp
omv
may
excess
provok
innat
immun
respons
lead
endotox
studi
gener
novel
omv
attenu
endotox
fmomv
modifi
structur
lipid
moieti
lp
investig
safeti
efficaci
fmomv
mucos
vaccin
adjuv
use
influenza
vaccin
model
fmomv
exhibit
attenu
endotox
compar
nativ
omv
nomv
intranas
inject
vaccin
antigen
fmomv
significantli
enhanc
system
mucos
immun
respons
furthermor
coadministr
fmomv
provid
protect
immun
homolog
heterolog
viru
challeng
suggest
potenti
fmomv
effect
mucos
adjuv
intranas
vaccin
fmomv
purifi
describ
previous
slight
modif
briefli
escherichia
coli
dmsbbdpagp
strain
transform
plasmid
encod
lipid
phosphatas
cultur
lb
broth
cultur
broth
filter
use
pores
filter
merck
nj
precipit
gl
ammonium
sulfat
solut
resuspend
pellet
suspens
centrifug
crude
fraction
purifi
perform
sucrosegradi
ultracentrifug
nomv
similarli
prepar
except
transform
procedur
composit
lipid
fmomv
analyz
describ
previous
briefli
cultur
e
coli
cell
incub
presenc
lciml
pi
h
collect
wash
cell
centrifug
pellet
dissolv
chloroformmethanolwat
vv
solut
insolubl
fraction
collect
hydrolyz
mm
sodium
acet
ph
contain
sd
min
mixtur
methanol
chloroform
ad
make
ratio
chloroformmethanolwat
vv
lower
phase
dri
cpm
sampl
run
silica
gel
tlc
plate
plate
visual
use
imag
analyz
fujifilm
tokyo
japan
hekblu
tm
cell
line
express
mous
invivogen
san
diego
ca
usa
cultur
media
life
technolog
carlsbad
ca
usa
supplement
fetal
bovin
serum
fb
ge
healthcar
littl
chalfont
uk
antibiot
life
technolog
resuspend
cell
hekbluetm
detect
media
life
technolog
cell
line
treat
nomv
fmomv
control
reagent
ly
merck
millipor
billerica
usa
lp
invivogen
flagellin
invivogen
incub
activ
secret
alkalin
phosphatas
determin
sixto
eightweekold
femal
mice
purchas
koatech
korea
kept
specif
pathogenfre
biosafeti
facil
korea
research
institut
bioscienc
biotechnolog
kribb
anim
treat
accord
guidelin
establish
institut
anim
use
care
committe
kribb
influenza
pandem
influenza
apuerto
influenza
aaquat
virus
cultiv
allanto
caviti
embryon
chicken
egg
virus
titrat
calcul
egg
infecti
dose
eid
store
use
mice
immun
intranas
trival
split
influenza
vaccin
antigen
contain
lg
subtyp
hamous
green
cross
korea
twice
twoweek
interv
purifi
fmomv
lghead
cholera
toxin
ct
list
biolog
laboratori
ca
mix
vaccin
antigen
immedi
inject
total
inject
volum
adjust
llmous
use
pb
two
week
second
inject
mice
challeng
ld
influenza
viru
bodi
weight
mortal
rate
monitor
two
week
human
endpoint
weight
loss
use
challeng
studi
dq
tm
ovalbumin
dqova
lghead
thermofish
scientif
deliv
intranas
lung
presenc
absenc
fmomv
lghead
h
mediastin
lymph
node
mln
cell
resuspend
fac
buffer
pb
contain
bovin
serum
albumin
sodium
azid
incub
fcblock
ebiosci
ca
wash
cell
stain
fluoresc
dyeconjug
antibodi
ebiosci
sampl
acquir
gallio
tm
beckman
coulter
ca
data
analyz
use
flowjo
softwar
tree
star
oh
two
four
week
first
immun
serum
bronchoalveolar
lavag
fluid
balf
sampl
analyz
antigen
ag
specif
igg
iga
enzym
linkedimmunosorb
assay
elisa
plate
thermofish
scientif
coat
vaccin
antigen
ngwell
incub
sampl
sequenti
incub
peroxidas
goat
antimous
total
igg
iga
cell
signal
technolog
substrat
bd
bioscienc
ca
ad
well
optic
densiti
measur
nm
wavelength
use
tm
perkinelm
determin
ha
stalkspecif
ab
ha
ha
polypeptid
express
e
coli
use
coat
antigen
subsequ
elisa
hemagglutin
inhibit
hi
assay
sera
pretreat
receptordestroy
enzym
rde
denka
seiken
japan
dilut
pb
viru
dilut
unit
mix
rdetreat
sera
min
ubottom
plate
spl
life
scienc
south
korea
chicken
red
blood
cell
suspens
ad
well
test
endpoint
determin
visual
inspect
agglutin
reaction
frequenc
influenzaspecif
ifncproduc
cell
determin
use
mous
ifnc
elispot
set
bd
bioscienc
briefli
total
splenocyt
cellswel
stimul
inactiv
viru
elispot
plate
coat
ifnc
captur
antibodi
forti
hour
later
plate
wash
sequenti
incub
biotinyl
ifnc
detect
antibodi
hrpconjug
streptavidin
ad
aec
substrat
spot
count
use
biospot
analyz
cellular
technolog
oh
viral
rna
extract
lung
homogen
mixtur
use
rneasi
mini
kit
qiagen
ca
follow
manufactur
protocol
real
time
revers
transcriptasepolymeras
chain
reaction
rtpcr
perform
use
quantitect
probe
rtpcr
kit
qiagen
roch
lightcycl
system
matrix
genespecif
primer
forward
gaccratcctgtcacctct
revers
specif
probe
use
statist
differ
among
group
assess
use
twotail
student
ttest
logrank
test
prism
softwar
graphpad
softwar
ca
p
consid
statist
signific
endotox
lp
highli
relat
structur
lipid
moieti
particularli
degre
acyl
previous
gener
e
coli
dmsbbdpagp
strain
produc
lp
lipid
pentaacyl
order
attenu
endotox
e
coli
lp
studi
introduc
lpxf
lipid
phosphatas
francisella
novicida
fig
size
purifi
fmomv
similar
nomv
rang
nm
diamet
morpholog
spheric
tabl
fig
addit
omv
similar
zeta
potenti
valu
approxim
mv
tabl
interestingli
fmomv
test
activ
divers
tlr
vitro
trigger
significantli
reduc
signal
compar
induc
nomv
p
wherea
omv
activ
similar
extent
fig
agreement
vitro
result
fmomv
show
significantli
lower
endotox
nomv
follow
deliveri
mice
nomv
result
signific
weight
loss
red
consolid
lung
tissu
day
intranas
administr
fmomv
caus
milder
weight
loss
inflamm
lung
fig
e
notabl
lg
fmomv
caus
bodi
weight
loss
pulmonari
inflamm
data
indic
fmomv
carri
pentaacyl
monophosphoryl
lipid
speci
reduc
activ
vitro
significantli
attenu
endotox
vivo
compar
nomv
previous
shown
coimmun
omv
increas
antigenspecif
immun
respons
codeliv
antigen
intramuscular
vaccin
model
investig
whether
intranas
deliveri
fmomv
effect
induc
strong
antigenspecif
immun
respons
inject
influenza
vaccin
antigen
variou
dose
fmomv
lg
intranas
two
week
second
immun
influenzaspecif
igg
respons
significantli
higher
three
group
administ
fmomv
compar
vaccinealon
group
p
respect
compar
cttreat
group
p
fig
antibodi
titer
also
significantli
increas
mice
coinject
fmomv
vaccin
p
fig
titer
exhibit
invers
relationship
escal
fmomv
dose
although
titer
decreas
fig
left
panel
titer
increas
fig
right
panel
consist
serum
igg
respons
hi
activ
viru
significantli
higher
fmomvcoimmun
group
lg
fmomv
compar
vaccin
aloneimmun
group
fig
sinc
cellmedi
adapt
immun
also
contribut
protect
influenza
infect
measur
frequenc
influenzaspecif
ifncsecret
cell
notabl
lg
fmomv
significantli
enhanc
antigenspecif
cell
respons
wherea
cell
respons
lgfmomvinject
group
compar
vaccinealon
inject
group
fig
collect
intranas
administr
fmomv
shown
enhanc
system
humor
cellular
respons
influenza
vaccin
verifi
coadministr
fmomv
modul
immun
respons
respiratori
mucosa
level
influenzaspecif
antibodi
balf
sampl
determin
dose
fmomv
fix
lg
amount
fmomv
suffici
increas
level
antibodi
cell
respons
without
result
toxic
vivo
fig
consist
serum
igg
level
fig
fmomv
significantli
increas
antigenspecif
igg
level
balf
p
vs
vaccin
alon
fig
left
panel
addit
secretori
iga
balf
play
import
role
protect
mucos
infect
dramat
increas
fmomvinject
group
compar
vaccinealon
immun
group
fig
right
panel
fmomv
coadministr
also
significantli
enhanc
influenzaspecif
cell
respons
lung
p
fig
sinc
fmomv
contain
divers
tlr
ligand
lp
lipoprotein
stimul
antigenpres
cell
apc
examin
chang
dc
mln
treatment
fmomv
dqova
model
antigen
dc
popul
mln
dramat
increas
intranas
administr
dqova
fmomv
compar
dqova
treatment
alon
vs
fig
left
panel
indic
activ
migrat
dc
tissu
drain
ln
fmomv
administr
addit
increas
number
dc
mln
exhibit
high
level
dqova
signal
antigen
uptak
upregul
fig
left
panel
dc
critic
induct
immun
respons
respiratori
tract
popul
loint
hi
lung
cell
increas
fmomv
administr
fmomvcoinject
dqova
aloneinject
group
respect
fig
left
panel
activ
phenotyp
dc
observ
nondrain
subiliac
ln
fig
right
panel
indic
fmomv
affect
dc
local
deliveri
site
data
show
intranas
vaccin
fmomv
activ
dc
lung
enhanc
antibodi
cell
respons
respiratori
mucosa
given
fmomv
effici
elicit
mucos
system
antigenspecif
immun
respons
next
examin
protect
efficaci
vaccin
fmomv
challeng
mice
lethal
dose
influenza
viru
dose
viru
intranas
administ
fmomvcoimmun
mice
lose
bodi
weight
demonstr
surviv
rate
three
group
p
fig
lung
viru
titer
also
significantli
reduc
vaccin
fmomv
p
dpi
respect
fig
verifi
fmomvcoimmun
confer
crossprotect
immun
requir
influenza
vaccin
challeng
mice
virus
monitor
bodi
weight
loss
surviv
rate
although
bodi
weight
decreas
day
challeng
viru
mice
show
gradual
recoveri
bodi
weight
exhibit
surviv
rate
p
fig
similarli
mice
challeng
viru
fmomvcoimmun
group
exhibit
signific
increas
surviv
rate
p
fig
even
though
fmomv
significantli
enhanc
influenzaspecif
adapt
immun
respons
protect
immun
viral
infect
possibl
fmomv
contribut
protect
efficaci
vaccin
induc
innat
immun
respons
respiratori
tract
verifi
innat
immun
contribut
observ
protect
efficaci
mice
inject
differ
dose
fmomv
alon
rang
lg
absenc
influenza
vaccin
antigen
challeng
week
later
ld
viru
day
post
infect
mice
began
lose
bodi
weight
irrespect
fmomv
dose
result
die
day
post
infect
fig
survivor
detect
group
given
lg
fmomv
surviv
rate
observ
howev
surviv
rate
group
statist
signific
compar
pb
group
p
indic
innat
immun
involv
protect
efficaci
observ
coadministr
fmomv
adjuv
therefor
data
togeth
previou
result
show
enhanc
adapt
immun
respons
fig
demonstr
vaccin
fmomv
provid
broad
protect
efficaci
homolog
heterolog
influenza
virus
base
adapt
immun
respons
sinc
influenza
virus
constantli
chang
antigen
characterist
mutant
new
variant
may
highli
infecti
transmiss
exemplifi
control
highli
infecti
variant
prevent
mass
infect
influenza
vaccin
need
provid
immedi
protect
immun
longterm
memori
immun
respons
check
whether
fmomvadjuv
vaccin
meet
requir
first
vaccin
mice
challeng
lethal
dose
viru
week
later
vaccin
fmomv
significantli
increas
surviv
rate
wherea
vaccin
alon
fail
protect
mice
p
fig
term
longterm
efficaci
mice
challeng
lethal
dose
influenza
viru
week
booster
immun
fmomvcoimmun
group
exhibit
similar
surviv
rate
compar
ctcoimmun
group
fig
indic
coadministr
fmomv
confer
prolong
protect
immun
data
show
intranas
vaccin
fmomv
induc
immedi
prolong
protect
immun
suggest
fmomv
could
use
vaccin
adjuv
pandem
situat
constant
emerg
fatal
respiratori
viral
diseas
highli
pathogen
influenza
middl
east
respiratori
syndrom
requir
efficaci
vaccin
increas
owe
efficaci
feasibl
intranas
administr
attract
method
deliv
vaccin
respiratori
virus
exemplifi
influenza
vaccin
therefor
promis
approach
develop
novel
mucos
adjuv
potenti
vaccineinduc
immun
respiratori
tract
studi
demonstr
effect
fmomv
intranas
vaccin
adjuv
use
influenza
vaccin
system
omv
show
potenti
vaccin
adjuv
immunostimulatori
activ
term
safeti
howev
nativ
omv
appli
vaccin
contain
fulli
endotox
lp
induc
excess
immun
activ
inflamm
endotox
lp
close
relat
degre
acyl
lipid
moieti
therefor
studi
gener
msbband
pagpdelet
strain
fig
lack
acyltransferas
palmitoyltransferas
requir
maximum
acyl
lipid
addit
introduc
lpxf
gene
encod
lipid
phosphatas
attenu
endotox
lp
gener
monophosphoryl
lipid
fig
expect
fmomv
produc
genet
engin
e
coli
show
much
greater
attenu
nomv
term
activ
vitro
toxic
vivo
fig
approach
agre
well
develop
monophosphoryl
lipid
adjuv
wide
rang
human
vaccin
lungresidenti
dc
particular
dc
play
pivot
role
induct
mucos
system
immun
respons
influenza
infect
dc
take
viral
antigen
migrat
drain
ln
initi
adapt
immun
respons
studi
observ
substanti
increas
lo
hi
popul
mln
h
fmomv
treatment
fig
dc
fmomvinject
mice
also
show
increas
level
activ
marker
antigen
uptak
signal
suggest
fmomv
stimul
dc
lung
lead
enhanc
adapt
immun
respons
consequ
increas
vaccin
efficaci
mechan
fmomv
modul
function
apc
vitro
vivo
current
investig
studi
observ
increas
protect
immun
heterolog
influenza
viral
infect
fmomvinject
group
compar
group
immun
vaccin
alon
fig
mani
adjuv
vaccin
target
cell
respons
shown
induc
crossreact
cell
respons
provid
protect
immun
heterolog
influenza
infect
addit
cell
respons
broadspecif
neutral
antibodi
known
crossprotect
serum
sampl
fmomvcoimmun
mice
weakli
bound
hastalk
antigen
elisa
suggest
fmomv
effici
induc
ha
stalkspecif
antibodi
respons
data
shown
ifnc
respons
significantli
increas
fmomvinfect
group
fig
appear
enhanc
cell
respons
mainli
contribut
increas
surviv
rate
fmomvcoimmun
group
even
though
differ
surviv
rate
group
challeng
heterolog
virus
one
challeng
homolog
viru
statist
signific
vs
respect
p
bodi
weight
group
receiv
heterolog
viru
challeng
tend
declin
earli
phase
infect
compar
group
receiv
homolog
viru
challeng
fig
upper
panel
vs
fig
left
panel
observ
suggest
crossreact
cell
respons
rather
crossreact
neutral
antibodi
respons
contribut
clearanc
viru
presum
remov
infect
cell
late
phase
infect
ctinject
group
clearli
show
revers
correl
titer
fig
observ
agre
well
fact
ct
potent
adjuv
fmomv
simultan
increas
decreas
titer
indic
fmomv
promot
immun
respons
fig
observ
support
fact
fmomv
strong
compon
lp
flagellin
bacteri
dna
fragment
contain
cpg
motif
nevertheless
unexpect
increas
dose
fmomv
downregul
antigenspecif
ifnc
respons
fig
one
possibl
explan
overactiv
apc
especi
dc
may
neg
regul
antigenspecif
cell
respons
secret
ifnc
coadministr
fmomv
provid
immedi
longlast
protect
immun
two
week
prime
immun
n
week
booster
immun
n
b
mice
challeng
viru
bodi
weight
chang
surviv
rate
monitor
week
data
repres
two
independ
experi
similar
result
p
p
turn
induc
express
ido
although
ido
well
known
suppress
cell
respons
deplet
tryptophan
b
cell
respons
appear
sensit
mechan
cell
respons
rather
ido
shown
activ
role
inflammatori
respons
correl
well
observ
cell
respons
decreas
increas
fmomv
dose
wherea
antibodi
respons
remain
high
fig
studi
requir
assess
underli
mechan
dosedepend
invers
correl
fmomv
dose
cell
respons
summar
gener
novel
omv
harbor
modifi
lipid
fmomv
manipul
gene
relat
acyl
phosphoryl
lipid
e
coli
evalu
safeti
efficaci
intranas
vaccin
adjuv
murin
influenza
model
coadministr
fmomv
provid
broad
protect
heterolog
viru
challeng
confer
immedi
prolong
immun
result
show
potenti
fmomv
intranas
vaccin
adjuv
prepared
influenza
pandem
